CDK4 and Familial prostate cancer: As DUB3 is activated after phosphorylation by CDK4 and CDK6 and E2F and MYC expression are activated after Rb phosphorylation by CDK4 and CDK6, treatment with the CDK4/CDK6 inhibitor Palbociclib sensitizes prostate cancer and NUT midline carcinoma cells to the BRD4 inhibitor JQ1, and exerts synergistic anticancer effects with JQ1 in vitro and in mouse models of castration-resistant prostate cancer and NUT midline carcinoma [45, 46].